Novo Nordisk posts strong 2026 start and Wegovy pill surge: Wegovy pill surpasses 2 million prescriptions since January launch
Obesity has officially overtaken oncology as largest contributor to biopharma pipeline value for first time in deloitte’s industry analysis, underscoring commercial momentum behind next-generation weight-loss therapies
Eli Lilly doubles down on its obesity franchise with a $4.5 billion expansion across its Indian manufacturing network
